Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Pharma
Merck's Winrevair cuts death, morbidity risk by 76%
Merck revealed data from a phase 3 study of Winrevair, which showed it reduced the risk of all-cause death, lung transplant or hospitalization by 76%.
Kevin Dunleavy
Mar 31, 2025 10:00am
After trial success, Merck halts a different Winrevair study
Jan 30, 2025 6:45am
Survey indicates Merck's Winrevair is set for 'strong uptake'
Jan 24, 2025 11:52am
Merck preps filings after Winrevair succeeds in severe PAH study
Nov 25, 2024 9:00am
Merck joins ALA's pulmonary arterial hypertension awareness push
Nov 14, 2024 10:50am
FDA balks at standard nod to Liquidia's PAH rival to United med
Aug 19, 2024 11:34am
